Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) announced that it has opened its first U.S.-based laboratory in the Boston-Cambridge area.
According to Defence, the new laboratory will allow the company to further develop and optimize its proprietary Accum technology for antibody-drug conjugates (ADCs).
In a statement, Sebastien Plouffe, CEO of Defence, stated, “Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics. Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market.”
